In one paragraphArticle in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
17 authors.
Akimasa AdachiDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Pengwei SunWu-Tsai Neuroscience Institute, Stanford University, Stanford, CA, USA.
Dingjingyu ZhouDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Yi Ran XuDepartment of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Qingyue LiWu-Tsai Neuroscience Institute, Stanford University, Stanford, CA, USA.
Edward P HarveyDepartment of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Andrew C KruseDepartment of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA. Andrew_Kruse@hms.harvard.edu.ORCID http://orcid.org/0000-0002-1467-1222 Funding
Making antibody generation rapid, scalable, and democratic through machine learning and continuous evolutionR01CA260415 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI KRUSE, ANDREW, LIU, CHANG C · 2020 to 2024
$8.4MProbing the specificity and activity of the metazoan Integrator complexR01GM134539 · NIGMS · HARVARD MEDICAL SCHOOL · PI Karen L Adelman, ERIC J WAGNER · 2019 to 2026
$4.7MTraining in Pharmacological SciencesT32GM132089 · NIGMS · HARVARD MEDICAL SCHOOL · PI DAVID E. GOLAN, Timothy J Mitchison · 2019 to 2026
$3.7MThe Conundrum of Absentee Receptors: Efficacy Potentiation Through Drug-Receptor ModulationR01AR081264 · NIAMS · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI MARK W. GRINSTAFF, Andrew Kruse · 2022 to 2026
$3.2MSustained Release Relaxin-2 for the Treatment of Frozen ShoulderR01AR079489 · NIAMS · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI MARK W. GRINSTAFF, Andrew Kruse · 2022 to 2026
$3.0MEngineering programmable enzymes for proteome editingDP2GM154013 · NIGMS · DANA-FARBER CANCER INST · PI Xin Zhou · 2023 to 2026
$2.7MHarvard Chemical Biology PhD ProgramT32GM139775 · NIGMS · HARVARD UNIVERSITY · PI Emily Patricia Balskus, PHILIP A COLE · 2022 to 2026
$2.6MLabel-free Optical Recording of Neuroelectric ActivitiesR01NS121934 · NINDS · STANFORD UNIVERSITY · PI CUI, BIANXIAO, MUELLER, HOLGER · 2021 to 2025
$2.2MTargeting cancer metastasis by inhibiting curvature-induced kinase activationR01CA311218 · NCI · STANFORD UNIVERSITY · PI Bianxiao Cui · 2025 to 2026
$2.0MInterrogating and rewiring cell signaling pathways in CAR-T cells with synthetic phosphotyrosine recognition domainsR00EB030587 · NIBIB · DANA-FARBER CANCER INST · PI ZHOU, XIN · 2022 to 2024
$733kEmploying biologics to probe GPCR signaling in maternal and fetal healthK99HD110612 · NICHD · HARVARD MEDICAL SCHOOL · PI SKIBA, MEREDITH ANNE · 2023 to 2024
$249kNCI NIH HHS R01 CA260415NCI NIH HHS R01 CA311218NIAMS NIH HHS R01 AR079489NIAMS NIH HHS R01 AR081264NIBIB NIH HHS R00 EB030587NICHD NIH HHS K99 HD110612NIGMS NIH HHS DP2 GM154013NIGMS NIH HHS R01 GM134539NIGMS NIH HHS T32 GM132089NIGMS NIH HHS T32 GM139775NINDS NIH HHS R01 NS121934
6 · The paper itselfAbstract
G-protein-coupled receptors (GPCRs) represent one of the most important yet incompletely addressed classes of therapeutic targets
Identifiers
PMID42816619
PMCPMC13632652
What Socratic holds
Textmetadata
Read underepoch 390